Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Pregnancy

Immune System Targeted for Research into New Rheumatoid Arthritis Treatments

Thomas R. Collins  |  March 20, 2017

WASHINGTON, D.C.—Researchers at the 2016 ACR/ARHP Annual Meeting discussed how they are exploring the immune system in search of groundwork for new rheumatoid arthritis (RA) treatments. The new avenues, supported by the Rheumatology Research Foundation, involve T cell adhesion, new understanding of the role of macrophages and insights into the way IgG glycans function. T…

Filed under:Meeting ReportsResearch RheumRheumatoid Arthritis Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)IgG glycansImmune SystemmacrophagePathogenesisResearchRheumatoid arthritisrheumatologyT cell adhesionTreatment

Oksana Kuzmina/shutterstock.comx

Environmental Factors in Pediatric Systemic Autoimmune Diseases

Lisa G. Rider, MD, & Frederick W. Miller, MD, PhD  |  March 20, 2017

Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

Filed under:Conditions Tagged with:air pollutionAutoimmune diseaseenvironmental factorgeneticInfectionJuvenile idiopathic arthritisKawasaki diseasepatient carePediatricsRheumatic DiseaserheumatologistriskSmoking

Syda Productions/shutterstock.com

Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars

Vanessa Caceres  |  February 15, 2017

Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications…

Filed under:Biologics/DMARDsDrug UpdatesPractice Support Tagged with:Association of Rheumatology Professionals (ARP)BiologicsDrugspatient carePractice ManagementQualityrheumatologistrheumatologySafetytherapyTreatment

RA Treatment Options: Researchers Explore Groundwork for New Therapies

Thomas R. Collins  |  February 7, 2017

WASHINGTON, D.C.—Researchers at the 2016 ACR/ARHP Annual Meeting discussed how they are exploring the immune system in search of groundwork for new rheumatoid arthritis (RA) treatments. The new avenues, supported by the Rheumatology Research Foundation, involve T cell adhesion, new understanding of the role of macrophages and insights into the way IgG glycans function. T…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:2016 ACR/ARHP Annual MeetingACR/ARHPACR/ARHP Annual Meetinghuman immunoglobulin GRheumatoid Arthritis (RA)Rheumatology Research FoundationT cellT cell adhesion

Rheumatology Awards, Appointments and Announcements for January 2017

Ann-Marie Lindstrom  |  January 19, 2017

New Rheumatologist at Minnesota Clinic Meghan Scheibe, MD, is pleased with her new position at CentraCare Clinic Rheumatology and Infusion Services, a hospital-based practice in St. Cloud, Minn. “It’s a great practice,” says Dr. Scheibe. “Young, energetic partners and wonderful support staff. I’m seeing four to six new patients a day.” These are patients who had…

Filed under:Career DevelopmentProfiles Tagged with:appointmentsAwardsCareerProfilespromotionrheumatologistrheumatology

Certolizumab Pegol Usage Compatible with Breastfeeding

Michele B. Kaufman, PharmD, BCGP  |  December 20, 2016

In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…

Filed under:Drug Updates Tagged with:breast milkbreastfeedingCertolizumab Pegolinfantspregnancy

A New Approach to Fracture Prevention

Susan Bernstein  |  December 14, 2016

Glucocorticoids are widely prescribed by rheumatologists, and the effects of daily and cumulative doses of these drugs on bone mineral density (BMD) are important elements of a draft clinical guideline document presented on Nov. 13 at the 2016 ACR/ARHP Annual Meeting in Washington, D.C. Leaders of the ACR guideline project discussed their recommendations at the…

Filed under:Clinical Criteria/GuidelinesConditionsMeeting ReportsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:2016 ACR/ARHP Annual Meetingdraft clinical guidelinefracture risk factorsFracturesGlucocorticoid-Induced OsteoporosisGlucocorticoid-Induced Osteoporosis Prevention and Treatment: An Updated ACR Clinical GuidelineGlucocorticoidsOsteoporosis

Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine

Megan L. Krause, MD, Vinicius Domingues, MD & Donald Miller, PharmD  |  November 16, 2016

Both due to its efficacy and favorable side effect profile when compared with alternative drugs for rheumatologic conditions, hydroxychloroquine is an important agent in rheumatologists’ armamentarium. However, one barrier to hydroxychloroquine use can be its effects on the eye (also see “Revised Retinopathy Screening Guidelines,”). Ocular side effects of hydroxychloroquine can include impact on the…

Filed under:Conditions Tagged with:eyeHYDROXYCHLOROQUINEocular diseaseophthalmalogistpatient careretinal toxicityRheumatic DiseaserheumatologistrisktherapyTreatmentvision

NYU Langone’s Division of Rheumatology in Manhattan Advances Its Mission to Understand Rheumatic Diseases, Improve Patient Outcomes

Gretchen Henkel  |  October 10, 2016

From its beginnings as the Rheumatic Diseases Study Group (RDSG) in the early 1930s, NYU Langone Medical Center’s Division of Rheumatology has been built on a tradition of research and clinical care. Today’s division, with 24 full-time and 76 part-time faculty members, continues to push toward understanding the pathogenesis of rheumatic diseases and interventions to…

Filed under:Education & TrainingProfilesResearch Rheum Tagged with:EducationgoalsManhattanNYU Langoneoutcomepatient careResearchRheumatic DiseaserheumatologistrheumatologyTraining

Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

Alexey Fomin, MD, & W. Neal Roberts, MD  |  October 10, 2016

The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Lupus nephritispatient carepopulationpregnancyResearchrheumatologyriskSLEtacrolimustherapy

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences